Cardiovascular Disease Connect
  • Saved
case study

Patient Background: An 82-year-old woman with severe symptomatic aortic stenosis was evaluated for transcatheter aortic valve replacement (TAVR). Her baseline electrocardiogram (ECG) showed right bundle branch block (RBBB) and a prolonged QRS duration.

Assessment and Diagnosis: She underwent TAVR. Her baseline right bundle branch block (RBBB; adjusted odds ratio [ORadj], 2.49) and each 1-millisecond increase in QRS duration (ORadj, 1.01) were identified as independent predictors of permanent pacemaker implantation (PPI).

Clinical Outcome: Approximately 21.5% of patients undergoing TAVR require PPI, most commonly due to third-degree atrioventricular (AV) block (46.4%).

Suggested Treatment Plan: When PPI is necessary, physiological pacing techniques—such as His-bundle or left bundle branch pacing—should be considered to minimize electromechanical dyssynchrony.

Patient Education: Patients should be counseled on the increased risk of PPI after TAVR and its association with higher long-term mortality.

Follow-up: Ongoing follow-up is essential. PPI is an independent predictor of mortality, with an estimated 7-year mortality of 43.3% in PPI recipients versus 30.9% in those without PPI.

  1. What ECG markers help predict pacemaker need post-TAVR? Answer Baseline right bundle branch block and increased QRS duration are key predictors. Prosthetic valve type, particularly self-expanding designs, also influences pacemaker need.
  2. What pacing strategies can reduce long-term mortality after TAVR? Answer His-bundle or left bundle branch pacing helps reduce dyssynchrony. In low-dependency cases, AV conduction algorithms are useful. Leadless pacing is promising but needs more data.
  • Saved
The impact of cardiovascular drugs on hyperglycemia and diabetes: a review of 'unspoken' side effects - PubMed

The impact of cardiovascular drugs on hyperglycemia and diabetes: a review of 'unspoken' side effects - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39393677/

Certain cardiovascular drugs significantly contribute to hyperglycemia and diabetes mellitus through various mechanisms. Effective management includes identifying at-risk individuals, choosing lower-risk medications, and implementing monitoring and preventive strategies. Further research...

Certain cardiovascular drugs can cause hyperglycemia via multiple mechanisms. This review outlines associated risks, individual factors, prevention strategies, and management to improve metabolic and cardiovascular outcomes.

  • Saved
Identification of potential therapeutic targets for nonischemic cardiomyopathy in European ancestry: an integrated multiomics analysis - PubMed

Identification of potential therapeutic targets for nonischemic cardiomyopathy in European ancestry: an integrated multiomics analysis - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39267096/

Based on European Ancestry Cohort, this study reveals that LILRA5 and NELL1 are potential therapeutic targets for NISCM, with LILRA5 showing particularly promising prospects in diabetic cardiomyopathy. Several small molecules...

 

LILRA5 and NELL1 were identified as potential drug targets for nonischemic cardiomyopathy using genetic and protein data; LILRA5 showed protective effects and promising small molecule interactions for therapy.

  • Saved
Risks and Benefits of Intermittent Fasting for the Aging Cardiovascular System - PubMed

Risks and Benefits of Intermittent Fasting for the Aging Cardiovascular System - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38354947/

Population aging and the associated increase in cardiovascular disease rates pose serious threats to global public health. Different forms of fasting have become an increasingly attractive strategy to directly address...

 

Intermittent fasting may improve cardiovascular health by addressing aging-related risk factors. While promising, further research is needed to confirm benefits and safety, particularly for elderly individuals at high risk.

  • Saved
ADA 2025 Highlights: Obesity Therapies, Islet Cell Advances, and Oral GLP-1 Outcomes in T2D

At ADA 2025, Dr. Mark Atkinson (University of Florida Diabetes Institute) highlighted the systemic benefits of obesity-targeted therapies, including cardiometabolic and cognitive improvements, while noting concerns about implementation and potential muscle loss. Emerging advances in stem cell–derived islet transplantation for type 1 diabetes show promise in reducing insulin dependence. Dr. John Buse (University of North Carolina) presented SOUL trial data indicating that oral GLP-1 receptor agonist therapy reduced major adverse cardiovascular events—CV death, nonfatal MI, or stroke—by 14%, with additional reductions in limb complications in high-risk patients with type 2 diabetes.